News and Announcements
Viralytics (ASX:VLA) – Investor and Shareholder Presentation
- Published July 23, 2013 10:53AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Viralytics is an Australian Stock Exchange listed company developing a portfolio of Oncolytic viruses that have the potential not only to provide a more effective treatment of a range of cancers, but also a substantial improvement in patients quality of life. Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics’ headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia.
Viralytics lead product CAVATAK™ has now entered the global phase II stage of clinical trial development with recruitment ongoing for a Phase II trial, treating Late Stage Melanoma patients – the CALM study. Viralytics New Drug (IND) application was allowed by the USA FDA, enabling this trial to be commenced in the USA during 2011. The Phase II trial will investigate the effectiveness of intratumourally administered CAVATAK™ in the treatment of Late Stage Melanoma.
Download the latest Investor & Shareholder Presentation below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
